Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00608803 | Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | PHASE1 | COMPLETED | 30 | — | — | Jan 1, 2008 | Jan 1, 2009 | Sep 17, 2009 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy. |
| Name | Type | Description |
|---|---|---|
| ZIO-201-T and doxorubicin | DRUG | ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm. |
Inclusion Criteria: * Age ≥18 years * Histological or cytological documentation of cancer * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Ifosfamide and doxorubicin naïve * Life expectancy of at least 12 weeks * Adequate bone marrow, liver, and re...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |